TB Gold Test: Why It’s Used and What Your Results Mean

The TB Gold test is a blood draw used to detect tuberculosis infection by measuring how your immune cells react to TB-specific proteins. Unlike the older skin test, it requires a single visit, delivers results within a day, and is unaffected by prior BCG vaccination, which makes it the preferred screening method for millions of people worldwide. The test is straightforward to get, but interpreting the result can be surprisingly nuanced, especially if you are on immune-suppressing medication, have recently been ill, or are being tested repeatedly over time as part of a workplace program.

What the Test Actually Measures

The formal name you will see on lab paperwork is QuantiFERON-TB Gold, sometimes abbreviated QFT-G or QFT. A newer version called QFT-Plus is now the standard in most labs, but the principle is the same. A technician draws your blood into special tubes that contain synthetic proteins found on the surface of Mycobacterium tuberculosis. If your white blood cells have encountered TB before, they recognize those proteins and release a signaling molecule called interferon-gamma. The lab measures the amount of interferon-gamma produced. A high response means your immune system has been primed by a TB infection at some point; a low response suggests it has not.

This is fundamentally different from the tuberculin skin test (TST), where a technician injects a small amount of purified protein derivative under your skin and you return two to three days later so someone can measure the resulting bump. The skin test reacts not only to TB but also to proteins shared by the BCG vaccine and some environmental bacteria. The TB Gold test sidesteps that problem because the synthetic proteins it uses are specific to the TB bacterium and are absent from BCG vaccine strains.

Why It Replaced the Skin Test in Many Settings

The CDC has recommended the QFT-G as an acceptable substitute for the skin test in every situation where the skin test would normally be used, including contact investigations, screening of recent immigrants, and routine surveillance of healthcare workers.¹ In practice, it has become the preferred choice in several specific scenarios.

The most common is screening people who received the BCG vaccine. BCG is given routinely in much of Asia, Africa, Latin America, and parts of Europe, so anyone born in those regions and later screened for TB in a country that does not use BCG frequently tests positive on the skin test even though they do not have a TB infection. One study of 100 BCG-vaccinated adults who had tested positive on the skin test found that only 30 percent also tested positive on the QFT-G.² The remaining 70 percent were likely reacting to the vaccine, not to actual TB. The strongest predictors of a true positive in that group were being born in a country with high TB rates, having a large skin-test bump of 16 mm or more, and having a chest X-ray that looked like healed TB.

The single-visit logistics also matter. Healthcare workers, people in correctional facilities, and newly arrived immigrants often face scheduling barriers that make a two-visit skin test impractical. With the blood test, everything happens in one appointment.

What a Positive Result Means

A positive TB Gold test means your immune system has encountered TB bacteria. It does not tell you whether the infection is latent or active. Latent TB means the bacteria are in your body but are being held in check by your immune system; you feel fine, you are not contagious, and you have no symptoms. Active TB means the bacteria are multiplying, causing illness, and potentially spreading to others. Most people with latent TB never develop active disease, but the risk exists, particularly if your immune system weakens later in life.

When the result comes back positive, the next step is usually a chest X-ray and a clinical evaluation. If the X-ray looks normal and you have no symptoms, your doctor will typically diagnose latent TB and discuss preventive treatment, which usually involves a course of antibiotics lasting three to four months. If the X-ray is abnormal or you have symptoms like a persistent cough, weight loss, or night sweats, additional testing, such as sputum cultures, is needed to rule out active disease.

Accuracy varies depending on your immune status. In people with healthy immune systems, the test has a sensitivity around 81 percent and a specificity around 96 percent for detecting active TB disease.³ In immunocompromised individuals, sensitivity drops to about 70 percent and specificity to about 91 percent. That gap is important if you are on drugs that suppress your immune system.

What a Negative Result Means

A negative result is generally reassuring. In a large prospective study, none of the immunocompromised individuals who tested negative on the QFT-Plus went on to develop active TB during follow-up, regardless of whether they received preventive therapy.⁴ That is a strong signal that a negative test carries real predictive value even in people whose immune systems are not at full strength.

That said, a negative result does not guarantee you are free of TB infection. False negatives do happen, and certain factors make them more likely. A retrospective study identified older age, having TB in sites outside the lungs, having a tumor, elevated white blood cell or neutrophil counts, and a skewed ratio of certain immune cell types as factors correlated with false-negative results.⁵ If your doctor strongly suspects TB based on your symptoms and exposure history, a negative blood test alone is unlikely to close the case. Additional testing, often including sputum analysis and imaging, will follow.

The Indeterminate Result Nobody Expects

Unlike a simple positive or negative, the TB Gold test can also come back indeterminate, which means the lab could not interpret it. This happens when your blood cells fail to respond adequately to the positive control tube in the test kit. Think of it as a quality check: if your immune cells cannot even mount a response to a known stimulant, the lab cannot trust that a lack of response to TB proteins is meaningful. About 3 percent of tests fall into this category, though rates vary sharply by population.⁶

Among healthcare workers, indeterminate results are rare, around half a percent. Among people about to start biologic therapies for conditions like rheumatoid arthritis or Crohn’s disease, the rate climbs to about 6 percent, because the underlying disease or existing immunosuppressive drugs dampen the immune response needed for a valid test. Low lymphocyte counts and low albumin levels have also been identified as independent predictors of indeterminate results.⁷

During the COVID-19 pandemic, indeterminate rates spiked. Severe COVID-19 and hospitalization were each associated with roughly four times the odds of an indeterminate result, and immunosuppressive medication, severe lymphopenia, and anemia each roughly doubled the odds.⁸ If you get an indeterminate result, the usual recommendation is to repeat the test once you have recovered from acute illness or once your immune status has improved. A skin test can also be used as a follow-up in some cases.

Screening Before Biologic Therapy

One of the most common reasons people encounter the TB Gold test is that they are about to start a biologic drug. Medications like TNF-alpha inhibitors (adalimumab, infliximab, etanercept) are widely prescribed for autoimmune conditions, but they suppress parts of the immune system that are critical for keeping latent TB in check. Reactivation of dormant TB in patients on these drugs can be life-threatening, so screening before starting therapy is standard practice.⁹

The challenge is that these patients sometimes already have compromised immune function from their underlying disease or from other immunosuppressive drugs they are taking. That makes both false negatives and indeterminate results more likely than in the general population. Clinicians often weigh the blood test result alongside the patient’s country of origin, prior TB exposure history, and chest X-ray findings rather than relying on the blood test alone.

How the Lab Can Affect Your Result

The test is more sensitive to handling than most people realize. Researchers have found that the amount of blood drawn into each tube and how vigorously the tubes are shaken after collection can shift results. In one study, underfilling the tubes to 0.8 mL produced a stronger immune response than filling to the standard 1.0 mL, and overfilling to 1.2 mL led to false-negative results in roughly 41 percent of people known to be infected.¹⁰ Vigorous shaking also elevated background levels in the control tube, potentially tipping borderline cases toward a positive reading.

Incubation time matters too. The manufacturer recommends 16 to 24 hours. Extending incubation to 48 or 72 hours did not improve sensitivity and actually increased the rate of indeterminate and false-positive results.¹¹ None of this means your result is unreliable, but it does mean that if your result is borderline or unexpected given your risk profile, lab handling could be a contributing factor worth discussing with your doctor.

Serial Testing and the Conversion-Reversion Problem

If you are a healthcare worker tested annually, you may eventually face a puzzling situation: a negative test one year, a positive the next, and a negative again the year after. This pattern of conversions and reversions is well documented and is one of the test’s most frustrating features in low-risk serial testing programs. Studies of American healthcare workers found that roughly 65 to 75 percent of those who converted from negative to positive later reverted back to negative on a subsequent test.¹²

The instability is concentrated in the borderline zone, near the test’s cutoff of 0.35 IU/mL. A study of Portuguese healthcare workers found that nearly half of those whose initial interferon-gamma level was just above the cutoff (between 0.35 and 0.7 IU/mL) reverted to negative on retest, whereas only about 5 percent of those with a strong initial response of 3.0 IU/mL or higher reverted.¹³ The practical lesson: if your test flips from negative to weakly positive during routine annual screening, there is a good chance it reflects biological noise rather than new infection. Many experts have called for a borderline zone or a higher cutoff to reduce false conversions in low-risk settings.

How It Compares to T-SPOT.TB

The TB Gold test is not the only blood test for TB. T-SPOT.TB is another interferon-gamma release assay that works on a similar principle but uses a different laboratory method: instead of measuring the total amount of interferon-gamma in a tube, it counts individual immune cells that respond to TB proteins. In head-to-head comparisons, T-SPOT.TB tends to be more sensitive overall, about 91 percent versus 80 percent for the QFT-GIT.¹⁴

The gap widens with age. Among adults under 30, both tests performed well, with sensitivities above 93 percent. But in people over 70, the TB Gold test’s sensitivity dropped to about 68 percent, while T-SPOT.TB held at roughly 86 percent. The age-related decline was statistically significant for the TB Gold test even after accounting for other variables. If you are older and your doctor is choosing between the two tests, this is a relevant consideration. T-SPOT.TB requires a separate processing step and is generally more expensive, which is why it is less commonly used as a first-line screening tool.

Testing Children

Using the TB Gold test in children has always been slightly controversial because most of the validation studies were done in adults. However, available data suggest the test performs well in pediatric populations. In one study of children with active TB, 17 out of 19 tested positive and none tested falsely negative, with the two remaining results classified as indeterminate rather than negative.¹⁵ The practical barrier in young children is the blood draw itself, which requires a minimum volume and can be difficult to obtain in very small kids. Some guidelines still favor the skin test in children under five, partly for logistical reasons.

The QFT-Plus Upgrade

If your test was ordered recently, you most likely received the QFT-Plus rather than the older QFT-Gold In-Tube. The key difference is that QFT-Plus includes an additional antigen tube designed to stimulate a broader immune response, engaging both CD4 and CD8 T-cells instead of primarily CD4 cells.¹⁶ The idea is that people with recent or active TB tend to have a stronger CD8 response, so the additional tube could help distinguish recent infection from remote exposure. In practice, the two test versions have performed comparably in most head-to-head studies, including among people living with HIV who have relatively preserved immune function.¹⁷

A newer rapid version called QIAreach QFT has also been developed. Instead of requiring a full laboratory setup, it uses a portable reader that delivers a result from the same blood sample. A meta-analysis found it has a pooled sensitivity of about 99 percent and a specificity of about 94 percent when compared against the standard QFT-Plus, with an essentially perfect negative predictive value.¹⁸ This could make the technology much more accessible in places without sophisticated lab infrastructure.

Cost and Practicality

The TB Gold test costs more upfront than the skin test, typically somewhere around two to four times the price depending on local lab fees. But the single-visit requirement eliminates the cost of a return appointment and the problem of people who never come back for their skin test reading. Economic modeling in European settings found that the blood test had lower overall costs than the skin test when indirect costs were included and that it was cost-effective at standard willingness-to-pay thresholds.¹⁹ A Colombian analysis similarly found the QFT-Plus cost-effective for diagnosing latent TB in people with healthy immune systems, though the result was sensitive to how common latent TB was in the population being screened; in groups where latent TB is rare, the skin test can be the more economical option.²⁰

When the Skin Test Still Makes Sense

Despite the advantages of the blood test, the skin test has not disappeared. It remains useful in certain situations. Very young children who may not tolerate a full blood draw are sometimes better served by the skin test. In resource-limited settings where refrigerated transport and laboratory equipment for the blood test are unavailable, the skin test is still the primary screening tool. And in some two-step screening strategies, a positive skin test is followed by a blood test to confirm the result, particularly in BCG-vaccinated populations. One study examining this approach found a statistically significant relationship between skin-test induration size and the likelihood of a confirmatory positive blood test, with larger bumps more likely to reflect true TB infection rather than BCG cross-reactivity.²¹

Neither test can distinguish latent from active TB, and neither can tell you when you were infected. Both are screening tools that flag immune memory of TB exposure. The real diagnostic workup for active disease always involves imaging, microbiological cultures, and clinical assessment. The TB Gold test’s contribution is getting that screening step done more accurately and more conveniently for the majority of people who need it.